Markets:

Overview

News

Currencies

International

Treasuries

Aptorum Group Limited - Class A Ordinary Shares (NQ:APM)

1.050 UNCHANGED

Streaming Delayed Price Updated: 10:14 AM EST, Jan 7, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Aptorum Group Limited - Class A Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9 Next >

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

January 20, 2022

Gainers TCR2 Therapeutics (NASDAQ:TCRR) s...

Via Benzinga

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

January 20, 2022

Gainers Aptorum Group (NASDAQ:APM) stock increased by 32.8% to $1.62 during Thursday's regular session. Aptorum Group's stock is trading at a volume of 86.4...

Via Benzinga

Stocks Roar Back to Life Despite Alarming Jobs Data ↗

January 20, 2022

Stocks are staging a massive comeback today, with the Dow Jones Industrial Average last seen up 428 points midday. Both the S&P 500 Index and Nasdaq Composite are sporting solid midday gains as well.

Via Talk Markets

Aptorum Shares Rise After FDA Orphan Drug Tag For Repurposed Compound For Pediatric Cancer ↗

January 20, 2022

The FDA has granted Orphan Drug Designation to Aptorum Group Limited (NASDAQ: APM) SACT-1, a repurposed small molecule compound for Neuroblastoma. Aptorum...

Via Benzinga

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

January 20, 2022

Gainers Baudax Bio (NASDAQ:BXRX) stock rose 32.2% to $0.26 during Thursday's pre-market session. The company's market cap stands at $21.9 million. Aptorum Group (...

Via Benzinga

Aptorum Group Receives FDA Orphan Drug Designation for its SACT-1 Repurposed Drug For The Treatment of Neuroblastoma

January 20, 2022

From Aptorum Group Limited

Via Business Wire

Aptorum Group Granted The First Patent for its SACT-1 Repurposed Drug For Treatment of Various Cancer Including but Not Limited to Neuroblastoma

January 18, 2022

From Aptorum Group Limited

Via Business Wire

Aptorum Group Announces Updates on the Clinical Validation of its RPIDD Infectious Disease Liquid Biopsy Technology

January 10, 2022

From Aptorum Group Limited

Via Business Wire

Aptorum Group Announces the Launch of its Oncology and Autoimmune Discovery and Development Platform Targeting Unmet Mutations and Novel Biomarkers

January 10, 2022

From Aptorum Group Limited

Via Business Wire

Aptorum Group Announces Completion of Phase I Clinical Trials for ALS-4 and SACT-1, Small Molecule Drugs Targeted for Infections Caused by Staphylococcus Aureus and Neuroblastoma

January 10, 2022

From Aptorum Group Limited

Via Business Wire

Aptorum Group Limited Announces Results of 2021 Annual General Meeting of Shareholders

December 03, 2021

From Aptorum Group Limited

Via Business Wire

Aptorum Group Limited to Hold Annual General Meeting of Shareholders on December 2, 2021

October 19, 2021

From Aptorum Group Limited

Via Business Wire

Aptorum Group Limited Interview to Air on Bloomberg U.S.

October 15, 2021

From Aptorum Group Limited

Via Business Wire

Aptorum To Start Testing SACT-1 In Neuroblastoma Patients ↗

September 15, 2021

The FDA has signed off Aptorum Group Limited's (NASDAQ: APM) IND application to initiate clinical trials of SACT-1 for neuroblastoma. The IND-opening trial is...

Via Benzinga

Aptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2021

September 15, 2021

From Aptorum Group Limited

Via Business Wire

Aptorum Group Limited Has Received IND Clearance From the US FDA to Initiate Clinical Trials for Repurposed Small Molecule Drug SACT-1 for the Treatment of Neuroblastoma

September 15, 2021

From Aptorum Group Limited

Via Business Wire

Aptorum Shares Move Higher After Interim Data From Staphylococcus Aureus Candidate ↗

July 12, 2021

Aptorum Group Limited (NASDAQ: APM) announces further interim data from its ongoing Phase 1 trial for ALS-4 targeting Staphylococcus aureus. Specifically,...

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

July 12, 2021

Gainers Celldex Therapeutics (NASDAQ:CLDX) stock rose 41.93% to $46.0 during Monday's pre-market session. The company's market cap stands at $1.8 billion. 180 Life...

Via Benzinga

Aptorum Group Announces Further Positive Interim Results of the Phase 1 Clinical Trial of ALS-4 Targeting Staphylococcus aureus

July 12, 2021

From Aptorum Group Limited

Via Business Wire

Aptorum Group Interview to Air on Bloomberg Television U.S. on the RedChip Money Report

July 09, 2021

From Aptorum Group Limited

Via Business Wire

58 Biggest Movers From Friday ↗

June 21, 2021

Gainers CAI International, Inc. (NYSE: CAI) shares surged 46.9% to close at $56.05 on Friday after the company agreed to a $1.1 billion takeover by Mitsubishi HC Capital Inc....

Via Benzinga

Aptorum Group CEO Subscribed Shares In The Company

May 26, 2021

From Aptorum Group Limited

Via Business Wire

54 Biggest Movers From Yesterday ↗

May 26, 2021

Gainers Flanigan's Enterprises, Inc. (NYSE: BDL) shares surged 40.6% to close at $34.90 on Tuesday after the company reported results for the 13 weeks and the 26 weeks ended...

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

May 25, 2021

Gainers Pieris Pharmaceuticals (NASDAQ:PIRS) stock moved upwards by 43.23% to $2.65 during Tuesday's regular session. As of 12:30 EST, Pieris Pharmaceuticals's...

Via Benzinga

42 Stocks Moving In Tuesday's Mid-Day Session ↗

May 25, 2021

Gainers SemiLEDs Corporation (NASDAQ: LEDS) shares surged 28.4% to $10.17 following reports indicating equipment billings increased 50% in April compared to the prior year's...

Via Benzinga

12 Health Care Stocks Moving In Monday's Intraday Session ↗

May 24, 2021

Gainers Scopus BioPharma (NASDAQ:SCPS) stock rose 101.34% to $12.0 during Monday's regular session. As of 12:30 EST, this security is trading at a volume of 17.5...

Via Benzinga

Mid-Day Market Update: Crude Oil Rises 2.5%; NGM Biopharmaceuticals Shares Plunge ↗

May 24, 2021

Midway through trading Monday, the Dow traded up 0.58% to 34,405.22 while the NASDAQ rose 1.43% to 13,663.92. The S&P also rose, gaining 1.04% to 4,199.05. The U.S. has the...

Via Benzinga

Topics Stocks

52 Biggest Movers From Yesterday ↗

May 25, 2021

Gainers Scopus BioPharma Inc. (NASDAQ: SCPS) shares climbed 72% to close at $10.25 on Monday after the company reported the FDA approval of IND application for CpG-STAT3siRNA,...

Via Benzinga

35 Stocks Moving In Monday's Mid-Day Session ↗

May 24, 2021

Gainers Scopus BioPharma Inc. (NASDAQ: SCPS) shares jumped 123.7% to $13.33 after the company reported the FDA approval of IND application for CpG-STAT3siRNA, its distinctive...

Via Benzinga

Aptorum's Shares Jump After ALS-4 Targeting Staphylococcus Aureus Shows Encouraging Action In Early-Stage Study ↗

May 24, 2021

Aptorum Group Limited (NASDAQ: APM) has completed two initial cohorts of the single-dose ascending dose (SAD) portion of the Phase 1 trial evaluating ALS-4...

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.